美国食品药物管理局于2010年拒绝批准Vivus公司的Qnexa,因为担心该药对孕妇的安全造成伤害,担心该药会加快患者的心率。
Vivus s new data apparently satisfied the FDA s advisory committee.
Vivus公司新的数据显然让管理局的咨询委员会满意。
However, the agency may yet reject the drug.
但是该局还是可能拒绝批准该药。
Even if Qnexa is approved, it is unclear that patients will buy it.
就算Qnexa获得批准,患者会不会买账仍不明了。
Qnexa combines two treatments that are already on the market.
Qnexa结合了两种市面上上有的疗效。
Both medicines are generic, which means that doctors may prescribe the existing drugsrather than Qnexa s more expensive version.
这两种药物都是非专利药,这说明医生可能会给患者开已有的药而不选择Qnexa,后者更贵。
For now, it is more profitable to treat fat patients than to try to make them slim.
到目前为止,治疗肥胖患者还是要比让他们减肥更有利可图。
【2015考研英语阅读点肥成金不现实】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30